Publication | Closed Access

Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches

VaccinationInfectious Disease ModellingValue-of-statistical-life ApproachesGlobal HealthEconomic BenefitsInternational HealthEpidemiological DynamicMiddle-income CountriesVaccine EfficacyInfection ControlPublic HealthVaccine HesitancyMedicineEpidemiology